4Q 2019 Results and preliminary annual report

14. Feb 2020 | 2 min read

Moss, 14 February 2020
 
Gentian Diagnostics AS announces its results for the 4th quarter and 2019 preliminary annual results.
 
The highlights include:
 
  • Record sales revenues of MNOK 14.1 in 4Q19, up from MNOK 11.1 in 4Q18, totaling a 27 % growth y/y
  • Total sales revenue for the year of MNOK 48.0 representing 20 % growth compared to 2018
  • Strong fCAL® turbo sales in Q4 resulting in a y/y growth of 112% driven by continued growth in kit sales and positive effect from bulk orders
  • fPELA development completed. External validation ongoing 

Please find the report and results presentation enclosed here:

14th Feb 2020 - Quarterly Report - Q4

14th Feb 2020 - Quarterly Presentation - Q4

 

For further information, please contact:

Hilja Ibert CEO, Gentian Diagnostics

E-mail: hilja.ibert@gentian.no

Cell Phone: +47 919 05 242

 

Njaal Kind CFO, Gentian Diagnostics

E-mail: njaal.kind@gentian.no

Cell Phone. +47 919 06 525

 

MeldingsID: 495485

UtstederID: GENT-ME

Marked: Merkur Market

You may also read


Dec 16, 2019 - Kristin Hart

Financial calendar

Financial calendar for Gentian Diagnostics AS

Dec 05, 2019 - Kristin Hart

Gentian Diagnostics presents at DNB conference in New York

Moss 05.12.19 The CEO of Gentian Diagnostics, Dr. Hilja Ibert, will today give a company presentation at the..